Timing of Onset of Garadacimab for Preventing Hereditary Angioedema Attacks
Clin Exp Allergy
.
2024 Dec;54(12):1020-1023.
doi: 10.1111/cea.14568.
Epub 2024 Oct 1.
Authors
Petra Staubach
1
,
Raffi Tachdjian
2
,
H Henry Li
3
,
Roman Hakl
4
,
Emel Aygören-Pürsün
5
,
Lolis Wieman
6
,
John-Philip Lawo
7
,
Timothy J Craig
8
9
Affiliations
1
Department of Dermatology and Allergy, University Medical Center Mainz, Mainz, Germany.
2
Division of Allergy and Clinical Immunology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
3
Institute for Asthma and Allergy, Chevy Chase, Maryland, USA.
4
Department of Clinical Immunology and Allergology, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
5
Department for Children and Adolescents, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
6
CSL Behring, King of Prussia, Pennsylvania, USA.
7
CSL Innovation GmbH, Marburg, Germany.
8
Allergy and Immunology, Tenured Professor of Medicine, Pediatrics and Biomedical Sciences, Hershey, Pennsylvania, USA.
9
Vinmec International Hospital, Times City, Hanoi, Vietnam.
PMID:
39353415
PMCID:
PMC11629047
DOI:
10.1111/cea.14568
No abstract available
Keywords:
attack free; early onset; garadacimab; hereditary angioedema; long‐term prophylaxis.
Grants and funding
CSL Behring